A director at Brenntag SE bought 7,000 shares at 57.369EUR and the significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Première publication du groupe Mobilux (BUT/Conforama)Rexel : amende de 124 m EUR de la part de l’Autorité de la concurrence (prix dérogés)Kering : S&P a dégradé le rating à BBB+/stableSynlab : Elliott va devenir actionnaire d’Ephios, ouvrant la voie au rachat des minoritaires>...
Synlab: Elliott will become shareholder of Ephios, paving the way for a squeeze-out of minority holdersRexel: France’s competition authority fines Rexel € 124m (special price agreement mechanism)Kering: S&P downgrades rating to BBB+/stableFirst publication of the Mobilux Group (BUT/Conforama)>...
We host the 15th edition of the Corporate Conference in cooperation with Commerzbank on September 3rd & 4th 2024 in Frankfurt am Main. This year we are welcoming 90 German small, mid and large cap companies. - >Adidas (+) – On trackAixtron (=) – No short-term inflection, but high confidence in long-term prospectsAllgeier (+) – Is confident it can achieve 15% EBITDA margin by the end of 2025 ams OSRAM (=) – Some cautiousness on auto/industrial, still co...
Ceconomy: 5.2% LfL growth in Q3 24, raise of sales guidance; EUR 144m 2026 bond remains outstanding 2026 bondholder will take over 2029 bond, Accentro publishes business plan updateTechem: potential IPO in September Brenntag: weak Q2 24 results, company revises down guidance again Avantor divests its clinical services business for USD 650m, aims to reduce indebtedness>...
Ceconomy: 5.2% LfL growth in Q3 24, raise of sales guidance; EUR 144m 2026 bond remains outstanding 2026 bondholder will take over 2029 bond, Accentro publishes business plan update Techem: potential IPO in September Brenntag: weak Q2 24 results, company revises down guidance again Avantor divests its clinical services business for USD 650m, aims to reduce indebtedness>...
>Op. EBITA better than expected in Q2, down 10% y-o-y adj. for FX to € 297m, 3% above the consensus of € 290m on higher q-o-q volumes and flat GP/ton - Op. EBITA sequentially benefited from a mix of volume recovery and stable GP/unit in Q2 2024 vs Q1 2024. Op. EBITA was up 14% q-o-q compared to Q1 2024, which reported € 260m op. EBITA, but declined 10% y-o-y adj. for FX to € 297m from € 332m, 3% above the consensus expectations of € 290m. Reshuffled Specialties segmen...
>Op. EBITA weaker than expected in Q1, down 24% y-o-y adj. for forex to € 260m against high comps, 7% below cons. at € 279m - Op. EBITA faced high a comparison base in Q1, down to € 260m from € 345m, 7% below consensus expectations of € 279m, reporting a 24% forex adj. decline fuelled by both segments, specialties (-23%) and essentials (-23% forex adj. y-o-y). Op EBITA was down 9% q-o-q compared to Q4 2023, which reported € 285m op. EBITA. Reshuffled specialties segme...
As Spring approaches, we see industry-wide destocking coming to an end, emerging recovery trends in China gaining momentum and European spot energy cost relief rolling in, all helping to restore plant utilisation and earnings. We add more cyclicality to our preferred names, upgrading BASF to Outperform (Neutral). Momentum being regained in specialties chemicals distribution triggers our upgrade of IMCD to Outperform (Neutral). ‘From record to record’ remains our mantra at FUCHS. ...
We are initiating coverage of Lonza with a target price of CHF 535 and an Outperform rating. As one of the world's leading contract development and manufacturing organisations (CDMO), Lonza is predestined to benefit from the sustainable drivers of this industry. The group's global presence and strong market positions in the growth areas of biologics and cell and gene therapy (CGT) will fuel double-digit sales growth and >30% EBITDA margins in the medium term. Despite significant growt...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.